Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation for Whom Oral Anticoagulation is Unsuitable

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 2628 participants.

Also called NCT07430956

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose prevention
Phase
Phase 3
Enrolled
  • 2,628 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07430956
  • EU CT 2025-521618-25-00
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Canada (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07430956. Randomized; quadruple masking; primary purpose prevention. Start 2026-04-03 (actual); primary completion 2029-03-28 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation for Whom Oral Anticoagulation is Unsuitable
Acronym
ROXI-INCLINE
Condition
Atrial Fibrillation (AF)
Intervention (Drug)
REGN7508
Intervention (Drug)
REGN9933
Intervention (Drug)
Placebo
Lead sponsor
Regeneron Pharmaceuticals (class: industry)

Record details

Record id
cardio:ct-nct07430956
Content hash
b07965521e743ecb85713eb566ab5ae68b16e0184e12b0eb30c712a36cd049ee